Skip Navigation


JAC Advance Access originally published online on January 22, 2007
Journal of Antimicrobial Chemotherapy 2007 59(3):556-559; doi:10.1093/jac/dkl525
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/3/556    most recent
dkl525v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ghannoum, M. A.
Right arrow Articles by Long, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghannoum, M. A.
Right arrow Articles by Long, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis

M. A. Ghannoum*, H. G. Kim and L. Long

Center for Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA

Received 26 July 2006; returned 2 October 2006; revised 28 November 2006; accepted 1 December 2006

* Corresponding author. Tel: +1-216-844-8580; Fax: +1-216-844-1076; E-mail: Mahmoud.Ghannoum{at}case.edu

Objectives: The objective of this study was to compare the activity of aminocandin, a new echinocandin with broad-spectrum activity against Candida spp., with that of amphotericin B, caspofungin and fluconazole, in an immunocompetent murine model of haematogenously disseminated candidiasis caused by a fluconazole-resistant Candida albicans.

Methods: Mice were infected with a fluconazole-resistant strain of C. albicans and treated with aminocandin 5 and 10 mg/kg intravenously (iv) once and twice weekly, amphotericin B 0.5 mg/kg iv every other day for 5 days, fluconazole 20 mg/kg orally (po) once a day for 5 days and caspofungin 0.5 mg/kg intraperitoneally (ip) once daily for 5 days.

Results: Treatment with aminocandin, given iv twice a week, resulted in 100% survival. Further, the tissue fungal burden of the aminocandin group was equivalent to that of amphotericin B (administered every other day) and caspofungin (administered daily).

Conclusions: Aminocandin may be an effective addition to the arsenal of antifungal compounds for the treatment of candidiasis caused by fluconazole-resistant C. albicans.

Keywords: echinocandins , Candida albicans , in vivo


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
G. E. Brzankalski, L. K. Najvar, N. P. Wiederhold, R. Bocanegra, A. W. Fothergill, M. G. Rinaldi, T. F. Pattterson, and J. R. Graybill
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
J. Antimicrob. Chemother., November 1, 2008; 62(5): 1094 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. C. Pasqualotto and D. W. Denning
New and emerging treatments for fungal infections
J. Antimicrob. Chemother., January 1, 2008; 61(suppl_1): i19 - i30.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.